Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine advances hepatitis C drug
The single dose ascending trial was conducted in patients with chronic hepatitis C virus (HCV) who have either failed or no longer respond to standard of care treatment.
The single dose ascending trial was conducted in patients with chronic hepatitis C virus (HCV) who have either failed or no longer respond to standard of care treatment.
Experiments, led by researchers at the Johns Hopkins Bloomberg School of Public Health, show CDDO-Im to be effective at doses 100 times lower than other compounds known to
As a first course of treatment, ovarian cancer is generally treated with surgery followed by a regimen of the chemotherapy drug cisplatin. However, cisplatin is not an effective
PSN010 is the second clinical candidate to emerge from the company’s discovery research efforts in diabetes. “We believe PSN010’s dual mechanism of action, which has been demonstrated in
The purpose of these studies will be to identify and validate clinical biomarkers and predictive algorithms for disease prognosis and therapeutic response. Under the agreement, Monogram and Dana-Farber
Retapamulin belongs to a new class of antibiotics and is being developed as a topical treatment for uncomplicated skin and skin structure infections due to susceptible strains of
Methylnaltrexone (MNTX) is a peripheral opioid receptor antagonist that is designed to treat rapidly the side effects of opioids without interfering with pain relief. Progenics is developing the
Gaucher disease is a lysosomal storage disorder resulting from an enzyme deficiency that can cause damage to the liver, spleen, bone marrow and in some cases, the central
The products will serve the cardiovascular, diabetic and central nervous system categories. Subject to FDA approval and patent expiries, the products will enter the US marketplace over the
Orphan products are developed to treat diseases or conditions that affect fewer than 200,000 people in the US. The orphan drug act provides a seven-year period of exclusive